PURPOSE: Spine fusion is the gold standard treatment in degenerative and traumatic spine diseases. The bone regenerative medicine needs (i) in vitro functionally active osteoblasts, and/or (ii) the in vivo induction of the tissue. The bone tissue engineering seems to be a very promising approach for the effectiveness of orthopedic surgical procedures, clinical applications are often hampered by the limited availability of bone allograft or substitutes. New biomaterials have been recently developed for the orthopedic applications. The main characteristics of these scaffolds are the ability to induce the bone tissue formation by generating an appropriate environment for (i) the cell growth and (ii) recruiting precursor bone cells for the proliferation and differentiation. A new prototype of biomaterials known as "bioceramics" may own these features. Bioceramics are bone substitutes mainly composed of calcium and phosphate complex salt derivatives. METHODS: In this study, the characteristics bioceramics bone substitutes have been tested with human mesenchymal stem cells obtained from the bone marrow of adult orthopedic patients. RESULTS: These cellular models can be employed to characterize in vitro the behavior of different biomaterials, which are used as bone void fillers or three-dimensional scaffolds. CONCLUSIONS: Human mesenchymal stem cells in combination with biomaterials seem to be good alternative to the autologous or allogenic bone fusion in spine surgery. The cellular model used in our study is a useful tool for investigating cytocompatibility and biological features of HA-derived scaffolds.
PURPOSE: Spine fusion is the gold standard treatment in degenerative and traumatic spine diseases. The bone regenerative medicine needs (i) in vitro functionally active osteoblasts, and/or (ii) the in vivo induction of the tissue. The bone tissue engineering seems to be a very promising approach for the effectiveness of orthopedic surgical procedures, clinical applications are often hampered by the limited availability of bone allograft or substitutes. New biomaterials have been recently developed for the orthopedic applications. The main characteristics of these scaffolds are the ability to induce the bone tissue formation by generating an appropriate environment for (i) the cell growth and (ii) recruiting precursor bone cells for the proliferation and differentiation. A new prototype of biomaterials known as "bioceramics" may own these features. Bioceramics are bone substitutes mainly composed of calcium and phosphate complex salt derivatives. METHODS: In this study, the characteristics bioceramics bone substitutes have been tested with human mesenchymal stem cells obtained from the bone marrow of adult orthopedic patients. RESULTS: These cellular models can be employed to characterize in vitro the behavior of different biomaterials, which are used as bone void fillers or three-dimensional scaffolds. CONCLUSIONS:Human mesenchymal stem cells in combination with biomaterials seem to be good alternative to the autologous or allogenic bone fusion in spine surgery. The cellular model used in our study is a useful tool for investigating cytocompatibility and biological features of HA-derived scaffolds.
Authors: James Kang; Howard An; Alan Hilibrand; S Tim Yoon; Eoin Kavanagh; Scott Boden Journal: Spine (Phila Pa 1976) Date: 2012-05-20 Impact factor: 3.468
Authors: William G De Long; Thomas A Einhorn; Kenneth Koval; Michael McKee; Wade Smith; Roy Sanders; Tracy Watson Journal: J Bone Joint Surg Am Date: 2007-03 Impact factor: 5.284
Authors: James N Weinstein; Jon D Lurie; Tor D Tosteson; Brett Hanscom; Anna N A Tosteson; Emily A Blood; Nancy J O Birkmeyer; Alan S Hilibrand; Harry Herkowitz; Frank P Cammisa; Todd J Albert; Sanford E Emery; Lawrence G Lenke; William A Abdu; Michael Longley; Thomas J Errico; Serena S Hu Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: F Salamanna; M Sartori; G Barbanti Brodano; C Griffoni; L Martini; S Boriani; M Fini Journal: Stem Cells Int Date: 2017-02-13 Impact factor: 5.443
Authors: Evangelos M Fragkakis; Jehan Jomaa El-Jawhari; Robert A Dunsmuir; Peter A Millner; Abhay S Rao; Karen T Henshaw; Ippokratis Pountos; Elena Jones; Peter V Giannoudis Journal: PLoS One Date: 2018-05-24 Impact factor: 3.240
Authors: Maria Rosa Iaquinta; Elisa Mazzoni; Marco Manfrini; Antonio D'Agostino; Lorenzo Trevisiol; Riccardo Nocini; Leonardo Trombelli; Giovanni Barbanti-Brodano; Fernanda Martini; Mauro Tognon Journal: Int J Mol Sci Date: 2019-01-31 Impact factor: 5.923
Authors: Carmen Lanzillotti; Monica De Mattei; Chiara Mazziotta; Francesca Taraballi; John Charles Rotondo; Mauro Tognon; Fernanda Martini Journal: Front Cell Dev Biol Date: 2021-04-09
Authors: Chiara Mazziotta; Carmen Lanzillotti; Maria Rosa Iaquinta; Francesca Taraballi; Elena Torreggiani; John Charles Rotondo; Lucia Otòn-Gonzalez; Elisa Mazzoni; Francesca Frontini; Ilaria Bononi; Monica De Mattei; Mauro Tognon; Fernanda Martini Journal: Int J Mol Sci Date: 2021-02-27 Impact factor: 6.208
Authors: Elisa Mazzoni; Antonio D'Agostino; Maria Rosa Iaquinta; Ilaria Bononi; Lorenzo Trevisiol; John Charles Rotondo; Simone Patergnani; Carlotta Giorgi; Michael J Gunson; G William Arnett; Pier Francesco Nocini; Mauro Tognon; Fernanda Martini Journal: Stem Cells Transl Med Date: 2019-12-13 Impact factor: 6.940